1. Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker
- Author
-
Mônica M. C. Becker, Gustavo F. A. Arruda, Diego R. F. Berenguer, Roberto O. Buril, Daniela Cardinale, and Simone C. S. Brandão
- Subjects
Cardiotoxicity ,18F-FDG PET/CT ,Anthracyclines ,Nuclear medicine ,Early diagnosis ,Cardio-oncology ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Highlights ∙ CTX related to chemotherapy is an important cause of heart failure in surviving cancer patients; ∙ Cardiomyocytes may increase their glycolytic metabolism under significant stress. This phenomenon has been observed in both experimental and clinical studies; ∙ PET/CT is a powerful noninvasive diagnostic technique that provides both anatomical and metabolic information; ∙ 18F-FDG is a glucose analog that is the most commonly used radiopharmaceutical in oncological PET/CT exams; ∙ The degree of myocardial 18F-FDG uptake may be a promising marker of the cardiomyocyte changes that precede cardiac dysfunction in the CTX cascade.
- Published
- 2023
- Full Text
- View/download PDF